1 Recruiting Study to evaluate the efficacy and safety of pritelivir versus foscarnet for HSV subjects resistant to Acyclovir HSV Infection Drug: Pritelivir
Drug: Foscarnet
Check Eligibility
2 Recruiting A Phase 1b, OL Study to Evaluate the PK, Safety & Efficacy of Biktarvy in HIV-1 infected, Virologically Suppressed, Pregnant Women in their Second and Third Trimesters-HIV RNA < 50 copies for > 6 months, GFR > 90, No HBV HIV-1 Infection Drug: B/F/TAF Check Eligibility
3 Recruiting A Phase 4, Randomized, Active-controlled, Open-label Study to Evaluate the Tolerability of Switching to Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/FAF) Once Daily Fixed-dose Combination (FDC) Regimen HIV-1 Infection Drug: D/C/F/TAF FDC
Drug: TAF/FTC FDC
Drug: INI Based Regimen
Check Eligibility
4 Recruiting Acute Hepatitis C (HCV) Infections: Safety and Efficacy of Glecaprevir (GLE)/Pibrentasvir (PIB) Hepatitis C Virus Drug: Glecaprevir/ Pibrentasvir Check Eligibility
5 Recruiting A Phase IIb, randomized, double-blind, parallel-group study to assess the efficacy, safety, tolerability, and resistance profile of GSK3640254 in combination with dolutegravir compared to dolutegravir plus lamivudine in HIV-1 infected, treatment-naive adults HIV-1 Infection Drug: GSK3640254
Drug: Dolutegravir
Drug: Lamivudine Capsules
Drug: Lamivudine Tablets
Check Eligibility
6 Recruiting A Randomized, Double-blind, Placebo-controlled, Phase 1b Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Multiple “Doses of ABBV-181 in HIV-1 infected Adults HIV-1 Infection Drug: ABBV-181
Drug: Placebo
Check Eligibility
7 Recruiting A Phase 1b Study to Evaluate the Safety and Tolerability of GS-1966/GS-1144 HIV Vaccine Regimens in Antiretroviral Treated People with HIV-1 HIV-1 Infection Check Eligibility
8 Recruiting A Phase 1b Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Doses of ABBV-382 in Persons Living with HIV-1 HIV-1 Infection Drug: ABBV-382
Drug: Placebo for ABBV-382
Check Eligibility